[1]汤信鹏,冯 娟,范晓棠.肝硬化合并消化道出血患者行内镜治疗后再出血预测模型的建立与验证[J].医学信息,2025,38(09):27-32.[doi:10.3969/j.issn.1006-1959.2025.09.005]
　TANG Xinpeng,FENG Juan,FAN Xiaotang.Establishment and Validation of a Predictive Model for Recurrent Bleeding in Liver CirrhosisPatients with Gastrointestinal Bleeding After Endoscopic Treatment[J].Journal of Medical Information,2025,38(09):27-32.[doi:10.3969/j.issn.1006-1959.2025.09.005]
点击复制

肝硬化合并消化道出血患者行内镜治疗后再出血预测模型的建立与验证()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年09期
页码:
27-32
栏目:
临床信息学
出版日期:
2025-05-01

文章信息/Info

Title:
Establishment and Validation of a Predictive Model for Recurrent Bleeding in Liver CirrhosisPatients with Gastrointestinal Bleeding After Endoscopic Treatment
文章编号:
1006-1959（2025）09-0027-06
作者:
汤信鹏; 冯 娟; 范晓棠
新疆医科大学第一附属医院消化病二科，新疆 乌鲁木齐 830054
Author(s):
TANG Xinpeng;  FENG Juan;  FAN Xiaotang
The Second Department of Gastroenterology, the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054, Xinjiang, China
关键词:
肝硬化; 消化道出血; 内镜治疗; 预测模型
Keywords:
Cirrhosis;  Gastrointestinal bleeding;  Endoscopic therapy;  Prediction model
分类号:
R573.2
DOI:
10.3969/j.issn.1006-1959.2025.09.005
文献标志码:
A
摘要:
目的 构建肝硬化合并上消化道出血患者行内镜治疗后再出血的预测模型，并验证此模型的预测价值。方法 纳入2017年1月-2021年12月我院收治的352例肝硬化伴消化道再出血患者作为研究对象，按患者内镜治疗后2年内是否发生消化道再出血分为未出血组199例和出血组153例。采用单因素及多因素Logistic回归分析肝硬化合并上消化道出血患者行内镜治疗后再出血的影响因素，基于独立预测因素构建列线图模型，绘制ROC曲线和决策曲线，分析独立预测因素及联合预测的预测效能和净收益率。结果 单因素分析显示，两组BMI、门静脉内径、Child-Pugh分级、食管胃底静脉曲张程度、Hp感染、门静脉血栓形成及出血量比较，差异有统计学意义（P＜0.05）；多因素Logistic回归分析显示，门静脉内径、Child-Pugh分级、食管胃底静脉曲张程度、Hp感染以及出血量为肝硬化合并消化道出血患者行内镜治疗后再出血的独立预测因素（P＜0.05）；构建列线图模型：P=1/（1+e-x），X=0.002×出血量（ml）+1×Child-Pugh分级（A=0，B=0.890，C=1.440）+1×食管胃底静脉曲张（轻度=0，中度=1.886，重度=2.773）+1.470×门静脉内径（cm）+2.574×Hp感染（是=1，否=0）-1.895；拟合优度（H-L）检验结果显示，肝硬化合并消化道出血患者行内镜治疗后再出血风险的的预测值与实际观测值符合度良好（?字2=0.305，P=0.815）；ROC分析显示，联合预测肝硬化合并消化道出血患者行内镜治疗后再出血的曲线下面积（AUC）为0.863（95%CI：0.824~0.902）；决策曲线分析显示，独立预测因素以及联合预测肝硬化合并消化道出血患者行内镜治疗后再出血均具有良好的净收益率。结论 本研究构建的列线图模型具有良好的预测效能和净收益率，能用于准确预测肝硬化合并消化道出血患者行内镜治疗后再出血风险。
Abstract:
Objective To establish a predictive model for recurrent bleeding in liver cirrhosis patients with upper gastrointestinal bleeding after endoscopic treatment, and to verify the predictive value of this model. Methods A total of 352 liver cirrhosis patients with gastrointestinal rebleeding admitted to our hospital from January 2017 to December 2021 were included as the study subjects. They were divided into a non bleeding group of 199 cases and a bleeding group of 153 cases according to whether the patients experienced gastrointestinal rebleeding within 2 years after endoscopic treatment. Univariate and multivariate logistic regression were used to analyze the influencing factors of rebleeding after endoscopic treatment in patients with liver cirrhosis complicated with upper gastrointestinal bleeding. A column chart model was constructed based on the independent predictive factors. ROC curves and decision curves were drawn, and the predictive efficiency and net return of independent predictive factors and joint prediction were analyzed. Results Univariate analysis showed that there were significant differences in BMI, portal vein diameter, Child-Pugh classification, degree of esophageal and gastric varices, Hp infection, portal vein thrombosis and bleeding volume between the two groups (P<0.05). Multivariate Logistic regression analysis showed that portal vein diameter, Child-Pugh classification, degree of esophagogastric varices, Hp infection and bleeding volume were independent predictors of rebleeding after endoscopic treatment in patients with cirrhosis and gastrointestinal bleeding (P<0.05). A column chart model was established: P=1/(1+e-x), X=0.002×bleeding volume (ml)+1×Child-Pugh grade (A=0, B=0.890, C=1.440)+1×Gsophageal and gastric varices (Mild=0, Moderate=1.886, Severe=2.773)+1.470×Portal vein diameter (cm)+2.574×Hp infection (Yes=1, No=0)-1.895. The result of goodness of fit (H-L) test showed that the predicted value of the risk of rebleeding after endoscopic treatment in liver cirrhosis patients with gastrointestinal bleeding was in good agreement with the actual observed value (?字2=0.305, P=0.815). ROC analysis results showed that the area under the curve (AUC) of predicting rebleeding in liver cirrhosis patients with gastrointestinal bleeding was 0.863 (95%CI: 0.824-0.902) after endoscopic treatment. The decision curve analysis results showed that independent predictive factors and combination predicting rebleeding in liver cirrhosis patients with gastrointestinal bleeding after endoscopic treatment had good net returns. Conclusion The column chart model constructed inthis study has good predictive performance and net return rate, and can be used to accurately predict the risk of rebleeding in liver cirrhosis patients with gastrointestinal bleeding after endoscopic treatment.

参考文献/References:

[1]林勇,曾欣,胡平方.中国肝硬化临床诊治共识意见[J].临床肝胆病杂志,2023,39(9):2057-2073.[2]Devarbhavi H,Asrani SK,Arab JP,et al.Global burden of liver disease:2023 update[J].Journal of Hepatology,2023,79(2):516-537.[3]中华医学会肝病学分会.肝硬化诊治指南[J].中华肝脏病杂志,2019,27(11):846-865.[4]韩晶,毛锦娟,吴时胜,等.肝硬化上消化道出血患者并发门静脉血栓形成的危险因素[J].中华实用诊断与治疗杂志,2018,32(6):571-574.[5]王松,单晶,夏勇,等.消化道出血行内镜治疗后再出血影响因素分析及列线图预测模型构建[J].现代医学,2023,51(8):1033-1042.[6]李莉,谭跃,黎振林,等.消化内镜治疗上消化道出血后再出血危险因素分析[J].贵阳医学院学报,2013,38(2):159-161.[7]Chang W,Cai L,Chen T,et al.Current Helicobacter pylori Infection Is Associated with Early Liver Injury:A Cross-Sectional Study in the General Population[J].Am J Trop Med Hyg,2023,108(4):684-692.[8]何晓荣,田尧,马林,等.乙肝病毒相关肝硬化并发急性上消化道出血的危险因素分析[J].临床消化病杂志,2024,36(1):36-38.[9]钟玉福,林明强,冯奇桃,等.肝硬化并发上消化道出血的危险因素及其Hp感染基因型与Foxp3和RORγt基因表达水平[J].中华医院感染学杂志,2023,33(12):1814-1818.[10]蒋梦真.肝硬化门脉高压症患者血流动力学与肝储备功能的关系[J].中国医师杂志,2020,22(3):385-389.[11]北京医师协会门静脉高压专科医师分会,中国研究型医院学会肝病专业委员会门静脉高压学组,中国研究型医院学会肝病专业委员会.肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识[J].临床肝胆病杂志,2021,37(9):2037-2044.[12]苏争艳,孙超,蒋肸慧,等.三种评分系统在肝硬化食管胃底静脉曲张破裂出血患者风险评估中的应用[J].中华消化内镜杂志,2020,37(2):105-110.[13]Zahmatkesh ME,Jahanbakhsh M,Hoseini N,et al.Effects of Exosomes Derived From Helicobacter pylori Outer Membrane Vesicle-Infected Hepatocytes on Hepatic Stellate Cell Activation and Liver Fibrosis Induction[J].Front Cell Infect Microbiol,2022,12(6):857570.[14]Elsebaey MA,Tawfik MA,Elshweikh SA,et al.Impact of Helicobacter pylori Infection on Gastric Variceal Bleeding among Patients with Liver Cirrhosis[J].Gastroenterol Res Pract,2019,10(3):6529420.[15]陈娟,薛建波,康晓,等.急性消化性溃疡患者反复上消化道出血的危险因素研究[J].中国急救复苏与灾害医学杂志,2023,18(4):510-513.[16]Gralnek IM,Camus Duboc M,Garcia-Pagan JC,et al.Endoscopic diagnosis and management of esophagogastric variceal hemorrhage:European Society of Gastrointestinal Endoscopy (ESGE) Guideline[J].Endoscopy,2022,54(11):1094-1120.[17]Del Río Izquierdo J,Ramos Belinchón C,Ba?觡ares R,et al.Esophagogastric variceal bleeding as a debut of Caroli’s syndrome[J].Rev Esp Enferm Dig,2022,114(11):678.[18]Baiges A,Hernández-Gea V.Management of Liver Decompensation in Advanced Chronic Liver Disease:Ascites,Hyponatremia,and Gastroesophageal Variceal Bleeding[J].Clin Drug Investig,2022,42(Suppl 1):25-31.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Journal of Medical Information,2018,31(09):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(09):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[4]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(09):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[5]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Journal of Medical Information,2019,32(09):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[6]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[7]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Journal of Medical Information,2019,32(09):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[8]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Journal of Medical Information,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[9]严 利,陈 娟.杜氏病致消化道出血案例分析[J].医学信息,2019,32(14):192.[doi:10.3969/j.issn.1006-1959.2019.14.065]
[10]曹 宇,何其顺,郭雅雯,等.延时扫描对肝硬化患者肝脏增强CT检查中动脉期时相的影响[J].医学信息,2020,33(01):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
　CAO Yu,HE Qi-shun,GUO Ya-wen,et al.Effect of Delayed Scanning on the Phase of the Middle Arterial Phase of Liver Enhanced CT in Patients with Cirrhosis[J].Journal of Medical Information,2020,33(09):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
[11]王 颖,王兰英.临床护理路径对肝硬化并消化道出血患者护理的效果及肝功能的影响[J].医学信息,2021,34(13):181.[doi:10.3969/j.issn.1006-1959.2021.13.051]
　WANG Ying,WANG Lan-ying.The Effect of Clinical Nursing Path on the Nursing Effect and Liver Function of Patients with Liver Cirrhosis and Gastrointestinal Bleeding[J].Journal of Medical Information,2021,34(09):181.[doi:10.3969/j.issn.1006-1959.2021.13.051]
[12]刘立楠.肝硬化患者上消化道出血危险因素与预后影响因素分析[J].医学信息,2021,34(14):3.[doi:10.3969/j.issn.1006-1959.2021.14.002]
　LIU Li-nan.Analysis of Risk Factors and Prognostic Factors of Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis[J].Journal of Medical Information,2021,34(09):3.[doi:10.3969/j.issn.1006-1959.2021.14.002]

更新日期/Last Update: 1900-01-01